An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy

Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez, Marta, Alonso‐Alonso, Ruth, Fernández‐Miranda, Ismael, Mondéjar, Rufino, Cereceda, Laura, Tráscasa, Álvaro, Antonio‐Da Conceiçao, Anabel, Borregón, Jennifer, Gato, Lucía, Tomás‐Roca, Laura, Bárcena, Carmen, Iglesias, Begoña, Climent, Fina, González‐Barca, Eva, Camacho, Francisca Inmaculada, Mayordomo, Émpar, Olmedilla, Gabriel, Gómez‐Prieto, Pilar, Castro, Yolanda, Serrano‐López, Juana, Sánchez‐García, Joaquín, Montes‐Moreno, Santiago, García‐Cosío, Mónica, Martín‐Acosta, Paloma, García, Juan F., Planelles, María, Quero, Cristina, Provencio, Mariano, Mahíllo‐Fernández, Ignacio, Rodríguez‐Pinilla, Socorro M., Derenzini, Enrico, Pileri, Stefano, Sánchez‐Beato, Margarita, Córdoba, Raúl, Piris, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422037/
https://www.ncbi.nlm.nih.gov/pubmed/36051055
http://dx.doi.org/10.1002/jha2.457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422037/
https://www.ncbi.nlm.nih.gov/pubmed/36051055
http://dx.doi.org/10.1002/jha2.457

Ejemplares similares